The Plasma Cell Neoplasm Spectrum
Multiple myeloma doesn't appear suddenly. It evolves through a well-defined precursor spectrum that every clinician should understand — because the management at each stage is fundamentally different, and early recognition of progression can be life-saving.
The spectrum begins with monoclonal gammopathy of undetermined significance (MGUS), progresses through smoldering multiple myeloma (SMM), and culminates in active multiple myeloma requiring treatment. Understanding where a patient falls on this spectrum — and recognizing when they're transitioning — is one of the most important skills in hematology.
MGUS: The Precursor State
MGUS is present in approximately 3-4% of the general population over age 50, making it one of the most common hematologic findings in clinical practice. It's defined by three criteria: serum M-protein <3 g/dL, bone marrow plasma cells <10%, and absence of end-organ damage (no CRAB criteria).
The critical clinical fact about MGUS is the progression rate: approximately 1% per year to multiple myeloma or a related malignancy. This means that over a 20-year period, roughly 20% of MGUS patients will progress. The challenge is identifying which patients will progress and which will remain stable.
Risk stratification for MGUS progression uses three factors: M-protein level ≥1.5 g/dL, non-IgG isotype, and abnormal serum free light chain ratio. Patients with all three risk factors have a 20-year progression risk of approximately 58%, while those with no risk factors have a risk of only 5%.
Management of MGUS is observation with regular monitoring — not treatment. The monitoring schedule depends on risk stratification: low-risk patients can be followed annually with SPEP and CBC, while high-risk patients warrant more frequent monitoring including serum free light chains.
Smoldering Multiple Myeloma
SMM represents the intermediate state between MGUS and active myeloma. It's defined by M-protein ≥3 g/dL or bone marrow plasma cells 10-59%, without end-organ damage. The progression rate is significantly higher than MGUS — approximately 10% per year for the first 5 years, then declining to 3% per year for the next 5 years.
The management of SMM has been one of the most debated topics in hematology. The landmark QuiRedex trial showed that early treatment of high-risk SMM with lenalidomide-dexamethasone improved overall survival compared to observation. However, the trial has been criticized for methodological limitations, and the standard of care remains observation for most SMM patients.
The 20/2/20 model is the current standard for risk-stratifying SMM: bone marrow plasma cells >20%, serum M-protein >2 g/dL, and serum free light chain ratio >20. Patients with 2 or more risk factors have a 2-year progression rate of approximately 50% and may be candidates for early intervention in clinical trials.
Active Multiple Myeloma: The CRAB Criteria and Beyond
Active multiple myeloma requiring treatment is defined by the presence of clonal bone marrow plasma cells ≥10% plus one or more myeloma-defining events. The classic myeloma-defining events are the CRAB criteria:
C — Calcium elevation (serum calcium >1 mg/dL above normal or >11 mg/dL). Hypercalcemia results from osteoclast activation and bone destruction.
R — Renal insufficiency (creatinine >2 mg/dL or creatinine clearance <40 mL/min). Caused by light chain cast nephropathy, hypercalcemia, or amyloid deposition.
A — Anemia (hemoglobin <10 g/dL or >2 g/dL below normal). Results from bone marrow infiltration and cytokine-mediated suppression of erythropoiesis.
B — Bone disease (one or more osteolytic lesions on skeletal survey, CT, or PET-CT). Myeloma bone disease is caused by uncoupled bone remodeling with increased osteoclast activity and suppressed osteoblast function.
In 2014, the IMWG added three biomarkers of malignancy (SLiM criteria) that define active myeloma even without CRAB features: bone marrow plasma cells ≥60%, serum free light chain ratio ≥100, and >1 focal lesion on MRI. These criteria allow earlier treatment initiation for patients at very high risk of imminent organ damage.
Current Treatment Landscape
The treatment of active multiple myeloma has been transformed over the past two decades. Current first-line therapy for transplant-eligible patients typically includes induction with a triplet or quadruplet regimen (e.g., VRd — bortezomib, lenalidomide, dexamethasone, with or without daratumumab), followed by autologous stem cell transplant and lenalidomide maintenance.
For transplant-ineligible patients, the standard is daratumumab-based combination therapy (DRd or DVMp) continued until progression. The addition of daratumumab to standard regimens has consistently improved progression-free survival across multiple trials.
The treatment landscape continues to evolve rapidly with bispecific antibodies (teclistamab, elranatamab) and CAR-T cell therapy (idecabtagene vicleucel, ciltacabtagene autoleucel) now available for relapsed/refractory disease. These therapies represent a paradigm shift in myeloma treatment and are being studied in earlier lines of therapy.
Tools for Clinical Practice
The complexity of the myeloma spectrum — from MGUS risk stratification through active disease staging and treatment selection — demands accessible, up-to-date clinical decision support. The Multiple Myeloma Educational Tool covers the complete spectrum with interactive algorithms for diagnosis, staging (ISS and R-ISS), and treatment selection. The Plasma Cell Disorders Reference extends coverage to related conditions including Waldenström macroglobulinemia, AL amyloidosis, and heavy chain diseases.